De­ci­pher­a's TKI drug flops key test in ear­li­er-line GI tu­mors, send­ing stock in­to a tail­spin

De­spite a very late line ap­proval for its TKI drug last year, De­ci­phera has had its eyes set on crack­ing in­to ear­li­er pa­tients with GI tu­mors — a pos­si­bil­i­ty in­vestors cheered. But that door has now been slammed shut, and De­ci­phera’s cheer­lead­ers are flee­ing in droves.

De­ci­phera’s Qin­lock (ripretinib) failed a head-to-head matchup against stan­dard-of-care suni­tinib in sec­ond-line pa­tients with gas­troin­testi­nal stro­mal tu­mors (GIST) who had pre­vi­ous­ly been treat­ed with TKI in­hibitor ima­tinib, the biotech ad­mit­ted Fri­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.